EBV-induced Lymphomas
2
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Epsteinbarr Virusspecific Cytotoxic T Lymphocytes Ebvctls
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Research Network
Common Treatments
- Epsteinbarr Virusspecific Cytotoxic T Lymphocytes Ebvctls1
- Ebvspecific T Cells Ebvctls1
Active Sponsors
- Atara Biotherapeutics2
- Memorial Sloan Kettering Cancer Center2
- National Cancer Institute (NCI)1
Top Investigators
Atara Biotherapeutics
Related Conditions
- Ebvassociated Malignancies2
- Transplant Patients With Ebv Viremia At High Risk For Developing A Recurrent Ebv Lymphoma1
- Transplant Patients With Ebv Viremia At High Risk Of Developing A Recurrent Ebv Lymphoma1